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Introduction
For more than 14 years, hemovigilance has aimed to prevent the occurrence of adverse reactions (AR) related to the transfusion of labile blood products (LBP). In order to reduce the viral residual risk (lower donor exposure), apheresis platelet concentrates (APC) are more often applied in platelet transfusion (80.5 versus 19.5%) than pooled platelet concentrates (PP). From 1995 to 2006, the amount of APC used in France has increased regularly: from 130,000 APC to 190,000 APC. On the other hand the amount of PP has decreased from 72,000 to 24,000 in 2002, but increased again to 43,000 in 2006. The present study aimed at evaluating the tolerance of these two kinds of LBP in terms of AR observed in recipients. We therefore screened the database of the national hemovigilance network that gives an exhaustive view of the AR notifications in France in combination with a complete traceability of the transfused LBP for AR possibly, probably or definitely attributable to the transfusion of these two types of platelet concentrates (PC) between January 1, 2000 and December 31, 2006.
The French Hemovigilance System
The Agence Française de Sécurité Sanitaire des Produits de Santé (Afssaps; French Health Products Safety Agency) is responsible for the organization and the functioning of the national hemovigilance network. In accordance with the French laws, all AR, regardless of their severity, are notified to the Afssaps by hemovigilance correspondents (in public and private hospitals as well as in blood establishments) on standardized forms (online reporting system). In France, we use five levels of seriousness and evidence each. Evidence Levels -Level 4: certain = conclusive evidence for attributing the AR to the blood transfusion. -Level 3: likely = evidence in favor of attributing the AR to the blood transfusion, without any other obvious causes. -Level 2: possible = evidence is indeterminate for attributing the AR either to the blood transfusion or to alternative causes.
Grade of Seriousness
-Level 1: doubtful = other possible causes but no evidence for excluding the role of the blood transfusion in the occurrence of the AR. -Level 0: excluded = conclusive evidence for attributing the AR to causes other than the blood transfusion.
Requirements of Hemovigilance
Requirements of hemovigilance are: -the notification of suspected AR observed in a recipient to the competent authority (Afssaps), -a high level of traceability, i.e. the ability to trace each individual unit of LBP from the donor to the recipient or disposal. Number of TIR for 1000 products (table 1) ). All notifications of AR (evidence level 2, 3, 4) from 2000 to 2006 were reported to blood products issued. We observed that the number of transfusion incident reports (TIR) is more than twice as high with APC (8.61:1,000 LBP) than with PP (4.21:1,000 LBP). The difference between these two ratios is statistically significant as shown by chi-square test (e = 21.00 with α = 5%) (table 2). The respective ratios for AR due to transfusion-transmitted bacterial infections (TTBI) are 0.0328:1000 APC and 0.0285:1000 PP, being not significantly different according to chi-square analysis (e = 0.320 with α = 5%). It could also be shown that the risk to suffer AR of any type, except for alloimmunization, is higher with APC than with PP, even though most of the AR (93%) are not serious ( fig. 2) . The most frequently observed AR related to APC and PP transfusion were allergic reactions. 10,025 allergic reactions were reported 6,258 of which were associated with APC transfusion. The risk of allergic reactions subsequent to APC and PP transfusion is 1:200 and 1:630, respectively (table 3) .
Source of Data
Conclusions and Discussion
The data of the French hemovigilance show that APC transfusion appears to be the greatest risk factor for AR of the 'allergy' type even if it should be remembered that allergic reactions are rarely serious. Nevertheless, only APC permits the manufacturing of an HLA-compatible PC. Since 2005, a slight decrease in the number of notified allergic reactions has been observed with APC. The impact of platelet additive solutions should be evaluated with the benefit of hindsight.
The new French national hemovigilance commission should impel a working group evaluating the topic of allergy and APC to put forward preventive measures.
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